Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA V Commitment Letter Front-Loads Guidance, Meeting Milestones

Executive Summary

It may not feel like it to exhausted user fee negotiators, but the release of FDA’s draft commitment letter for PDUFA V signals the start of more long campaigns for the agency and pharmaceutical companies.

You may also be interested in...



FDA Hunting For Ways To Expand Patient Role In Drug Development

Agency’s Patient Network Annual Meeting will help explain the drug development process along with agency and patient roles as part of ongoing effort to increase patient involvement.

Everything REMS Under The Sun: FDA Lays Out Ambitious PDUFA V Meeting Agenda

The struggles that industry and FDA face when trying to best standardize and evaluate REMS are illustrated by the dozens of topics jammed into the two-day meeting.

FDA Plans To Improve REMS Effectiveness With Guidance On Goals And Metrics

The agency cited the forthcoming guidance in response to an HHS Inspector General report that questions the effectiveness of the risk management program.

Related Content

Topics

UsernamePublicRestriction

Register

PS053742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel